Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

SLDB

Solid Biosciences Inc

Feb 06 • 04:00PM ET

6.52

+0.29 4.65 %

Healthcare • Biotechnology • USA • NASD

Peers: SRPT PFE BMRN BLUE QURE EDIT RGEN NTLA ABEO VYGR

| Held by: VTI IWM IWN VXF IBB VTWO DFAS IWC PRFZ VFMO

Index	RUT	P/E	-	EPS (ttm)	-2.49	Insider Own	24.44%	Shs Outstand	77.88M	Perf Week	0.93%
Market Cap	507.97M	Forward P/E	-	EPS next Y	-2.06	Insider Trans	-2.00%	Shs Float	58.87M	Perf Month	16.22%
Enterprise Value	293.77M	PEG	-	EPS next Q	-0.50	Inst Own	83.47%	Short Float	14.61%	Perf Quarter	65.90%
Income	-167.13M	P/S	-	EPS this Y	31.42%	Inst Trans	2.07%	Short Ratio	8.30	Perf Half Y	5.33%
Sales	0.00M	P/B	2.33	EPS next Y	1.98%	ROA	-68.82%	Short Interest	8.60M	Perf YTD	15.60%
Book/sh	2.80	P/C	2.15	EPS next 5Y	14.41%	ROE	-86.83%	52W High	7.37 -11.53%	Perf Year	114.47%
Cash/sh	3.03	P/FCF	-	EPS past 3/5Y	32.97% 41.25%	ROIC	-70.35%	52W Low	2.41 170.54%	Perf 3Y	-13.53%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.14% 6.54%	Perf 5Y	-93.30%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	17.88%	Oper. Margin	-	ATR (14)	0.37	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.74	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	58.53	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.74	EPS Q/Q	38.60%	SMA20	6.24%	Beta	2.64	Target Price	15.75
Payout	-	Debt/Eq	0.10	Sales Q/Q	-	SMA50	12.06%	Rel Volume	1.82	Prev Close	6.23
Employees	100	LT Debt/Eq	0.09	Earnings	Nov 03 AMC	SMA200	24.68%	Avg Volume	1.04M	Price	6.52
IPO	Jan 26, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-9.34% -	Trades		Volume	1,886,482	Change	4.65%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-04-25	Initiated	Needham	Buy	$16
Jun-26-25	Initiated	Citigroup	Buy	$14
Jan-08-25	Initiated	Truist	Buy	$16
Dec-13-24	Initiated	Wedbush	Outperform	$16
Dec-10-24	Initiated	JMP Securities	Mkt Outperform	$15
Jul-15-24	Upgrade	JP Morgan	Neutral → Overweight	$10 → $15
Jun-24-24	Upgrade	Leerink Partners	Market Perform → Outperform	$12
May-31-24	Resumed	Piper Sandler	Overweight	$20
Mar-28-24	Initiated	William Blair	Outperform	$40
Mar-15-24	Initiated	Citigroup	Buy	$16
Mar-14-24	Upgrade	Piper Sandler	Neutral → Overweight	$8 → $20
Dec-08-23	Initiated	H.C. Wainwright	Buy	$9
Jul-12-21	Initiated	Piper Sandler	Neutral	$6
May-27-21	Initiated	Jefferies	Buy	$7
Mar-16-21	Upgrade	SVB Leerink	Mkt Perform → Outperform	$3 → $15
Mar-09-21	Initiated	Barclays	Overweight	$13
Jan-08-21	Upgrade	Credit Suisse	Underperform → Neutral	$2 → $7
Jul-28-20	Downgrade	SVB Leerink	Outperform → Mkt Perform
May-07-20	Downgrade	Evercore ISI	Outperform → In-line
Oct-11-19	Initiated	Evercore ISI	Outperform	$22

Show Previous Ratings

Today 08:00AM	Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-26-26 02:49PM	Sarepta Stock Climbs. 3-Year Study Results for Elevidys Bring Hope. (Barrons.com)
Jan-16-26 09:08AM	Will KROS Stock's Restructuring Efforts Reap Rewards for Investors? (Zacks)
Jan-15-26 12:58PM	JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy success (Pharmaceutical Technology)
Jan-13-26 04:15PM	Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101 (GlobeNewswire) +12.60%
04:15PM	Loading…
Jan-12-26 04:15PM	Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia (GlobeNewswire)
08:05AM	Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia (GlobeNewswire)
Jan-06-26 08:00AM	Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-05-26 04:15PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-16-25 04:51PM	Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services (GlobeNewswire) -7.56%
Dec-15-25 11:10PM	Sarepta's Elevidys Safety Concerns Open Major Opportunity for Solid Biosciences' (SLDB) SGT-003 in Duchenne Therapy (Insider Monkey)
Dec-08-25 08:00AM	Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum (GlobeNewswire)
Dec-02-25 06:54AM	Solid Biosciences' SGT-212 gains FDA rare paediatric disease status (Pharmaceutical Business Review)
Dec-01-25 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia (GlobeNewswire)
08:00AM	Loading…
Nov-17-25 08:00AM	Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101 (GlobeNewswire)
Nov-11-25 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire) +9.16%
Nov-06-25 08:00AM	Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy (GlobeNewswire) +7.25%
Nov-04-25 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -15.29% -10.78%
Nov-03-25 04:05PM	Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions (GlobeNewswire)
Oct-30-25 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
Oct-01-25 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Solid Biosciences to Present at Upcoming Scientific Meetings (GlobeNewswire)
Sep-25-25 08:00AM	Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting (GlobeNewswire) -5.13%
Sep-23-25 08:00AM	Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101 (GlobeNewswire)
Sep-18-25 09:10AM	Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics (PR Newswire)
Aug-28-25 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-12-25 04:07PM	Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) +10.60%
03:33PM	Brutal 2025 for Sarepta-Analysts Still Call for 179% Upside (MarketBeat)
Aug-01-25 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Loading…
Jul-23-25 08:00AM	Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) (GlobeNewswire) +8.51%
Jul-21-25 08:30AM	Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors (GlobeNewswire)
Jul-09-25 10:17AM	Citi Initiates Coverage on Solid Biosciences Inc. (SLDB) with 'Buy' Rating and $14 PT (Insider Monkey) +5.34%
Jul-08-25 04:05PM	Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) (GlobeNewswire) +6.72%
Jul-01-25 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.54% +5.87%
Jun-26-25 09:49AM	General Mills upgraded, Trade Desk downgraded: Wall Street's top analyst calls (The Fly)
Jun-18-25 11:39AM	Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences (MarketBeat)
Jun-03-25 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-28-25 08:00AM	Solid Biosciences to Participate at the Jefferies Global Healthcare Conference (GlobeNewswire) +7.24%
May-15-25 04:06PM	Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) +6.95%
May-01-25 04:00PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.27% +18.08%
Apr-30-25 08:00AM	Solid Biosciences to Participate at The Citizens Life Sciences Conference (GlobeNewswire) +8.52%
Apr-29-25 08:00AM	Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting (GlobeNewswire) -5.57%
Apr-08-25 04:50PM	Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space (Seeking Alpha) -9.18%
07:30AM	Can Solid Biosciences Challenge Sarepta in the DMD Market? (MarketBeat)
Apr-07-25 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire) -5.62%
Apr-01-25 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.89%
07:00AM	Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors (GlobeNewswire)
Mar-26-25 12:31PM	5 Reasons To Buy Regenxbio Right Now (SeekingAlpha) -5.12%
Mar-14-25 10:29PM	Solid Biosciences Inc. (SLDB): Among Top Insider Purchases Last Month (Insider Monkey) +5.30%
Mar-12-25 08:00AM	Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (GlobeNewswire)
Mar-07-25 09:55AM	Wall Street Analysts Believe Solid Biosciences (SLDB) Could Rally 198.18%: Here's is How to Trade (Zacks)
Mar-06-25 04:16PM	Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-05-25 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire) +8.47%
Mar-04-25 08:33PM	Is Solid Biosciences Inc. (SLDB) Among Stocks With At Least $20 Million In Insider Spending Recently? (Insider Monkey)
04:07PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-19-25 08:02AM	Solid Biosciences stock soars on early success in DMD gene therapy trial (Clinical Trials Arena) +22.08%
Feb-18-25 07:00AM	Solid Biosciences Announces Pricing of Underwritten Offering (GlobeNewswire) +31.51%
06:45AM	Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003 (GlobeNewswire)
06:36AM	Solid says early data suggest differentiated Duchenne gene therapy (BioPharma Dive)
Feb-09-25 06:12AM	Analysts Predict Up to ~450% Surge for These 2 Strong Buy Penny Stocks (TipRanks)
Feb-04-25 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-21-25 08:30AM	Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia (GlobeNewswire)
Jan-15-25 04:05PM	Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines (GlobeNewswire)
Jan-08-25 04:05PM	Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -8.68%
Jan-07-25 04:15PM	Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia (GlobeNewswire)
Jan-06-25 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-23-24 04:05PM	Solid Biosciences Added to the Nasdaq Biotechnology Index (GlobeNewswire)
Dec-13-24 01:52PM	Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst (Benzinga)
Dec-04-24 08:05AM	Solid Biosciences reports inducement grant under Nasdaq listing rule (TipRanks)
08:00AM	Solid Biosciences Announces Collaboration with Mayo Clinic to Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies (GlobeNewswire)
Dec-03-24 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -10.54%
Nov-26-24 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
Nov-14-24 08:00AM	Solid Biosciences to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-06-24 04:05PM	Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -6.03%
Nov-04-24 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-31-24 08:00AM	Solid Biosciences to Participate at the Truist Securities BioPharma Symposium (GlobeNewswire)
Oct-02-24 04:15PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-23-24 08:00AM	Solid Biosciences to Participate at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-12-24 08:00AM	Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-04-24 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-13-24 04:08PM	Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) +14.54%
Aug-05-24 08:00AM	Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-01-24 04:19PM	Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.58%
08:00AM	Solid Biosciences Joins the Russell 3000 Index (GlobeNewswire)
Jun-21-24 07:52AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jun-04-24 04:00PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-20-24 06:00AM	3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off (InvestorPlace)
May-15-24 12:53PM	SLDB Stock Earnings: Solid Biosciences Meets EPS for Q1 2024 (InvestorPlace)
07:52AM	Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results (GlobeNewswire)
May-07-24 07:00AM	Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
May-02-24 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.23%
Apr-03-24 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-02-24 10:35AM	Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug (Zacks)
07:20AM	Solid Biosciences' SGT-003 receives rare pediatric disease designation (Pharmaceutical Business Review)
Apr-01-24 07:45AM	Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003 (GlobeNewswire) -6.61%
Mar-28-24 04:08PM	How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback (Investor's Business Daily) -6.53%
Mar-27-24 07:00AM	Solid Biosciences to Participate at Cantor's Virtual Muscular Dystrophy Symposium (GlobeNewswire) +5.01%
Mar-13-24 07:44AM	Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results (GlobeNewswire) +7.28%

Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Howton David T	Chief Operating Officer	Feb 04 '26	Sale	6.44	18,894	121,713	97,859	Feb 06 06:05 PM
Cumbo Alexander	President and CEO	Feb 04 '26	Sale	6.44	48,913	315,093	222,018	Feb 06 06:01 PM
Ganot Ilan	Director	Feb 04 '26	Sale	6.44	7,205	46,414	25,271	Feb 06 06:01 PM
Tan Kevin	CFO & Treasurer	Feb 04 '26	Sale	6.44	14,783	95,231	94,201	Feb 06 06:00 PM
Brooks Gabriel	Chief Medical Officer	Feb 04 '26	Sale	6.44	12,616	81,271	84,092	Feb 06 05:59 PM
Hanrahan Jessie	Chief Regulatory Officer	Feb 04 '26	Sale	6.44	12,348	79,545	70,327	Feb 06 05:57 PM
Herzich Paul	Chief Technology Officer	Feb 04 '26	Sale	6.44	10,905	70,249	69,067	Feb 06 05:56 PM
Tan Kevin	Officer	Feb 04 '26	Proposed Sale	6.44	14,783	95,227		Feb 04 07:48 PM
Herzich Paul	Officer	Feb 04 '26	Proposed Sale	6.44	10,905	70,247		Feb 04 07:46 PM
Ganot Ilan	Director	Feb 04 '26	Proposed Sale	6.44	7,205	46,412		Feb 04 07:45 PM
Cumbo Alexander	Officer	Feb 04 '26	Proposed Sale	6.44	48,913	315,080		Feb 04 07:44 PM
Howton David T	Officer	Feb 04 '26	Proposed Sale	6.44	18,894	121,708		Feb 04 07:42 PM
Hanrahan Jessie	Officer	Feb 04 '26	Proposed Sale	6.44	12,348	79,541		Feb 04 07:40 PM
Brooks Gabriel	Officer	Feb 04 '26	Proposed Sale	6.44	12,616	81,268		Feb 04 07:37 PM
Tan Kevin	CFO & Treasurer	Feb 02 '26	Sale	6.44	26,837	172,747	108,984	Feb 02 08:18 PM
Cumbo Alexander	President and CEO	Feb 02 '26	Sale	6.44	80,258	516,613	270,931	Feb 02 08:16 PM
Hanrahan Jessie	Chief Regulatory Officer	Feb 02 '26	Sale	6.44	26,535	170,803	82,675	Feb 02 08:15 PM
Brooks Gabriel	Chief Medical Officer	Feb 02 '26	Sale	6.44	28,335	182,390	96,708	Feb 02 08:14 PM
Howton David T	Chief Operating Officer	Feb 02 '26	Sale	6.44	37,771	243,128	116,753	Feb 02 08:12 PM
Herzich Paul	Chief Technology Officer	Feb 02 '26	Sale	6.44	26,250	168,969	79,972	Feb 02 08:09 PM
Hanrahan Jessie	Officer	Feb 02 '26	Proposed Sale	6.44	26,535	170,803		Feb 02 08:07 PM
Brooks Gabriel	Officer	Feb 02 '26	Proposed Sale	6.44	28,335	182,390		Feb 02 08:05 PM
Tan Kevin	Officer	Feb 02 '26	Proposed Sale	6.44	26,837	172,747		Feb 02 08:04 PM
Cumbo Alexander	Officer	Feb 02 '26	Proposed Sale	6.44	80,258	516,613		Feb 02 08:03 PM
Howton David T	Officer	Feb 02 '26	Proposed Sale	6.44	37,771	243,128		Feb 02 08:01 PM
Herzich Paul	Officer	Feb 02 '26	Proposed Sale	6.44	26,250	168,969		Feb 02 07:59 PM
Ganot Ilan	Director	Jan 28 '26	Sale	6.59	191	1,259	17,476	Jan 30 04:05 PM
Tan Kevin	CFO & Treasurer	Jan 13 '26	Sale	5.27	5,704	30,060	46,100	Jan 13 05:02 PM
Tan Kevin	Officer	Jan 13 '26	Proposed Sale	5.27	5,704	30,060		Jan 13 05:00 PM
Ganot Ilan	Director	Jan 05 '26	Sale	5.43	1,053	5,718	17,278	Jan 06 06:52 PM
Howton David T	Chief Operating Officer	Dec 03 '25	Sale	5.11	4,932	25,203	32,908	Dec 04 04:22 PM
Cumbo Alexander	President and CEO	Dec 03 '25	Sale	5.11	10,808	55,229	81,388	Dec 04 04:20 PM
Hanrahan Jessie	Chief Regulatory Officer	Dec 03 '25	Sale	5.11	4,483	22,908	26,660	Dec 04 04:19 PM
Herzich Paul	Chief Technology Officer	Dec 03 '25	Sale	5.11	2,701	13,802	26,622	Dec 04 04:17 PM
Cumbo Alexander	Officer	Dec 03 '25	Proposed Sale	5.11	10,808	55,229		Dec 03 05:07 PM
Ganot Ilan	Director	Nov 10 '25	Sale	4.12	3,278	13,505	95,412	Nov 13 04:05 PM
Brooks Gabriel	Chief Medical Officer	Oct 20 '25	Sale	5.96	2,895	17,254	33,819	Oct 21 04:05 PM
Kahn Clare	Director	Mar 11 '25	Buy	5.34	1,860	9,924	2,960	Mar 13 04:05 PM
Bain Capital Life Sciences Inv	10% Owner	Feb 19 '25	Buy	4.03	1,000,000	4,030,000	5,034,582	Feb 21 05:48 PM
PERCEPTIVE ADVISORS LLC	Director	Feb 19 '25	Buy	4.03	5,000,000	20,150,000	11,833,539	Feb 21 04:17 PM
Adage Capital Management, L.P.	10% Owner	Feb 18 '25	Buy	7.56	252,545	1,909,240	4,248,084	Feb 19 04:16 PM
Hanrahan Jessie	Chief Regulatory Officer	Feb 14 '25	Sale	3.96	3,079	12,193	19,281	Feb 18 04:05 PM
Brooks Gabriel	Chief Medical Officer	Feb 14 '25	Sale	3.96	3,256	12,894	22,812	Feb 18 04:05 PM
Tan Kevin	CFO & Treasurer	Feb 14 '25	Sale	3.96	3,164	12,529	32,250	Feb 18 04:05 PM
Howton David T	Chief Operating Officer	Feb 14 '25	Sale	3.96	5,561	22,022	24,789	Feb 18 04:05 PM
Herzich Paul	Chief Technology Officer	Feb 14 '25	Sale	3.96	2,688	10,644	18,388	Feb 18 04:05 PM
Cumbo Alexander	President and CEO	Feb 14 '25	Sale	3.96	11,365	45,005	60,717	Feb 18 04:05 PM
Ganot Ilan	Director	Feb 14 '25	Sale	3.96	1,711	6,776	14,839	Feb 18 04:05 PM
Howton David T	Officer	Feb 14 '25	Proposed Sale	3.96	5,561	22,022		Feb 14 05:25 PM
Herzich Paul	Officer	Feb 14 '25	Proposed Sale	3.96	2,688	10,644		Feb 14 05:25 PM
Tan Kevin	Officer	Feb 14 '25	Proposed Sale	3.96	3,164	12,529		Feb 14 05:23 PM
Cumbo Alexander	Officer	Feb 14 '25	Proposed Sale	3.96	11,365	45,005		Feb 14 05:23 PM
Hanrahan Jessie	Officer	Feb 14 '25	Proposed Sale	3.96	3,079	12,193		Feb 14 05:20 PM

Open in Screener

OLMA

Olema Pharmaceuticals Inc

Feb 06 • 04:00PM ET

25.36

+0.35 1.40 %

Healthcare • Biotechnology • USA • NASD

OLMA Olema Pharmaceuticals Inc daily Stock Chart

Peers: AMGN GILD VRTX REGN BIIB ONC INCY NBIX EXEL ACAD

| Held by: VTI IWM XBI IWN IBB VXF VTWO SCHA DFAS IWC

Index	RUT	P/E	-	EPS (ttm)	-1.81	Insider Own	16.13%	Shs Outstand	68.65M	Perf Week	-1.40%
Market Cap	1.99B	Forward P/E	-	EPS next Y	-2.24	Insider Trans	-6.21%	Shs Float	65.97M	Perf Month	-6.32%
Enterprise Value	1.67B	PEG	-	EPS next Q	-0.52	Inst Own	74.24%	Short Float	13.79%	Perf Quarter	218.99%
Income	-149.96M	P/S	-	EPS this Y	12.92%	Inst Trans	-2.50%	Short Ratio	2.40	Perf Half Y	437.29%
Sales	0.00M	P/B	5.66	EPS next Y	-17.08%	ROA	-51.48%	Short Interest	9.10M	Perf YTD	1.44%
Book/sh	4.48	P/C	6.06	EPS next 5Y	-3.01%	ROE	-59.22%	52W High	36.26 -30.06%	Perf Year	282.50%
Cash/sh	4.18	P/FCF	-	EPS past 3/5Y	-7.01% -83.00%	ROIC	-48.25%	52W Low	2.86 786.71%	Perf 3Y	420.74%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.91% 7.11%	Perf 5Y	-39.27%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	17.23%	Oper. Margin	-	ATR (14)	1.90	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.03	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	46.68	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	8.03	EPS Q/Q	18.40%	SMA20	-4.40%	Beta	1.93	Target Price	45.60
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	-7.77%	Rel Volume	0.25	Prev Close	25.01
Employees	96	LT Debt/Eq	0.01	Earnings	Nov 10 BMO	SMA200	111.19%	Avg Volume	3.79M	Price	25.36
IPO	Nov 19, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-3.24% -	Trades		Volume	962,217	Change	1.40%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-26	Initiated	Piper Sandler	Overweight	$40
Oct-08-25	Initiated	Guggenheim	Buy	$20
Aug-12-25	Reiterated	Citigroup	Buy	$20 → $21
Apr-02-24	Initiated	Goldman	Buy	$24
Jan-30-24	Initiated	Citigroup	Buy	$20
Jul-21-23	Initiated	Oppenheimer	Outperform	$21
May-05-23	Initiated	CapitalOne	Overweight	$16
Feb-22-23	Initiated	Credit Suisse	Outperform	$12
Jul-06-22	Resumed	Canaccord Genuity	Buy	$16
Jun-09-22	Upgrade	H.C. Wainwright	Neutral → Buy	$12
Feb-28-22	Initiated	H.C. Wainwright	Neutral
Dec-07-21	Resumed	Cowen	Outperform
Dec-14-20	Initiated	JP Morgan	Overweight	$52
Dec-14-20	Initiated	Jefferies	Buy	$70
Dec-14-20	Initiated	Cowen	Outperform
Dec-14-20	Initiated	Canaccord Genuity	Buy	$60

Show Previous Ratings

Feb-04-26 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.05%
Feb-03-26 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-30-26 04:01PM	Olema Oncology Announces Departure of Chief Operating and Financial Officer (GlobeNewswire)
09:47AM	LifeSci Capital Reiterates a Buy on Olema Pharmaceuticals (OLMA) (Insider Monkey)
Jan-21-26 05:59AM	Piper Sandler Puts its Weight Behind 2 Strong Buy Cancer Stocks (TipRanks)
04:30PM	Loading…
Jan-05-26 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-25 10:19AM	Olema (OLMA) Hits 4-Year High as Jefferies Hikes PT (Insider Monkey)
Dec-02-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-24-25 05:45PM	This strategist is 'following the money' on these stock picks (Yahoo Finance Video) +8.11%
Nov-21-25 04:30PM	Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference (GlobeNewswire) +5.27%
Nov-20-25 04:01PM	Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +13.28%
Nov-19-25 11:50AM	Olema Pharmaceuticals Has Nearly Tripled on Cancer Drug Hopes. How Should You Play OLMA Stock Here? (Barchart)
07:00AM	Olema Oncology Announces Pricing of $190.0 Million Public Offering of Common Stock (GlobeNewswire)
Nov-18-25 04:51PM	Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +136.38%
04:21PM	Loading…
04:21PM	Why biotech and drug stocks are on the mend even though the rest of the market is hurting (MarketWatch)
09:20AM	Why Roche's Positive Test Results Sent Olema Pharma Skyrocketing 200% (Investor's Business Daily)
Nov-10-25 07:00AM	Olema Oncology Reports Third Quarter 2025 Financial and Operating Results (GlobeNewswire)
Nov-04-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-03-25 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.13%
Oct-30-25 04:30PM	Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025 (GlobeNewswire)
Oct-18-25 03:00AM	Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025 (GlobeNewswire)
Oct-16-25 04:33PM	Guggenheim Initiates Olema Pharmaceuticals (OLMA) Coverage with Buy Rating and $20 PT, Cites Palazestrant Potential (Insider Monkey) -7.43%
Oct-02-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-30-25 11:41AM	Goldman Sachs Raises Stake in Olema Pharmaceuticals, Inc. (OLMA) (Insider Monkey)
Sep-12-25 10:38AM	OLMA Stock Soars 47% in September So Far on Second PFE Deal (Zacks)
Sep-03-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-02-25 07:00AM	Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer (GlobeNewswire) +18.50%
Aug-20-25 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-14-25 12:30PM	Biotech Stocks Rally as Oncology Market Targets $866B by 2034 (PR Newswire)
01:15AM	Loading…
Aug-13-25 01:15AM	Clinical Trial Progress and Analyst Endorsement Spark Short-Term Rebound for Olema Pharmaceuticals (Insider Monkey)
Aug-11-25 04:01PM	Olema Oncology Reports Second Quarter 2025 Financial and Operating Results (GlobeNewswire) +16.19%
Aug-04-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-02-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-03-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.43%
May-28-25 07:00AM	Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting (GlobeNewswire)
May-21-25 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
09:55AM	Wall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals (OLMA): Can the Stock Really Move This High? (Zacks)
May-13-25 04:01PM	Olema Oncology Reports First Quarter 2025 Financial and Operating Results (GlobeNewswire)
May-09-25 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-02-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.24%
Apr-25-25 01:00PM	Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025 (GlobeNewswire)
Apr-24-25 09:55AM	Wall Street Analysts Think Olema Pharmaceuticals (OLMA) Could Surge 433.13%: Read This Before Placing a Bet (Zacks)
Apr-10-25 09:35AM	After Plunging -30.16% in 4 Weeks, Here's Why the Trend Might Reverse for Olema Pharmaceuticals (OLMA) (Zacks) +8.25%
Apr-08-25 04:25PM	Olema Pharmaceuticals: Maybe Not Differentiated, But Could Find A Niche In A Valuable Market (Seeking Alpha)
Apr-02-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-25-25 04:31PM	Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting (GlobeNewswire)
Mar-18-25 04:01PM	Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results (GlobeNewswire) -6.97%
Mar-04-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-19-25 04:30PM	Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-18-25 07:00AM	Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary (GlobeNewswire)
Feb-04-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.46%
Feb-03-25 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-03-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.75% -6.62%
Jan-02-25 07:00AM	Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-10-24 07:00AM	Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium (GlobeNewswire)
Dec-09-24 07:00AM	Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor (GlobeNewswire) -9.67%
Dec-03-24 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:17AM	Novartis and Olema expand alliance with $250m to boost breast cancer trials (Pharmaceutical Technology)
Dec-02-24 07:00AM	Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement (GlobeNewswire)
Nov-25-24 05:30PM	Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium (GlobeNewswire) +9.09%
Nov-24-24 07:27PM	Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors (PR Newswire)
Nov-12-24 04:01PM	Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -9.28%
Nov-06-24 07:01AM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-04-24 04:44PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-23-24 07:00AM	Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024 (GlobeNewswire)
Oct-09-24 07:00AM	Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-02-24 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-04-24 04:49PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-21-24 07:00AM	Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-06-24 04:02PM	Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -9.90%
Aug-02-24 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -14.22%
Aug-01-24 08:50AM	Recent Price Trend in Olema Pharmaceuticals (OLMA) is Your Friend, Here's Why (Zacks)
Jul-02-24 04:29PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.55%
Jun-14-24 07:05PM	TruBridge, Evans Bancorp, and More Stocks See Action From Activist Investors (Barrons.com)
Jun-04-24 04:28PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +18.96%
May-28-24 07:03AM	Olema Oncology to Participate in Upcoming Investor Conferences in June (GlobeNewswire)
May-15-24 07:01AM	Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress (GlobeNewswire)
May-08-24 10:58PM	OLMA Stock Earnings: Olema Pharmaceuticals Misses EPS for Q1 2024 (InvestorPlace) -9.31%
04:02PM	Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
07:02AM	Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress (GlobeNewswire)
May-03-24 12:15PM	Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 (PR Newswire) +5.96%
May-02-24 04:37PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-01-24 07:02AM	Olema Oncology to Participate in Upcoming Investor Conferences in May (GlobeNewswire)
Apr-08-24 04:30PM	Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference (GlobeNewswire) +5.33%
Apr-05-24 12:16AM	Goldman Sachs Predicts Over 120% Rally for These 2 Strong Buy Stocks (TipRanks)
Apr-02-24 04:29PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-11-24 04:03PM	Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -6.62%
Mar-06-24 07:03AM	Olema Oncology Announces Publication of Data Highlighting Palazestrant's Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors (GlobeNewswire)
Mar-04-24 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.01%
Feb-06-24 07:01AM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-02-24 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-22-24 10:54AM	15 Small-Cap Stocks with High Potential (Insider Monkey)
Jan-08-24 08:12AM	Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate (GlobeNewswire)
Jan-02-24 04:01PM	Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-21-23 10:59AM	Hedge Fund and Insider Trading News: 3G Capital, Elliott Management, Harbor Capital, Three Arrows Capital, Nucor Corporation (NUE), Olema Pharmaceuticals, Inc. (OLMA), and More (Insider Monkey)
Dec-05-23 12:27PM	Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies (GlobeNewswire) -15.34%
Dec-04-23 04:29PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-01-23 09:30AM	Top Stocks for December 2023 (Investopedia)
Nov-28-23 05:10PM	Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS) (GlobeNewswire)

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Harmon Cyrus	Director	Jan 20 '26	Sale	26.88	10,000	268,800	727,770	Jan 21 09:00 PM
Harmon Cyrus	Director	Jan 20 '26	Proposed Sale	26.88	10,000	268,763		Jan 20 04:13 PM
Harmon Cyrus	Director	Jan 14 '26	Sale	29.12	3,489	101,600	737,770	Jan 16 09:00 PM
Kovacs Shane William Charles	CH. OPERATING & FINANCIAL OFF.	Jan 15 '26	Sale	28.73	100,000	2,873,000	139,727	Jan 15 09:00 PM
Kovacs Shane William Charles	CH. OPERATING & FINANCIAL OFF.	Jan 13 '26	Sale	28.01	3,822	107,054	239,727	Jan 15 09:00 PM
Kovacs Shane William Charles	Officer	Jan 15 '26	Proposed Sale	28.73	100,000	2,873,215		Jan 15 04:22 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Jan 13 '26	Option Exercise	4.87	50,000	243,500	592,761	Jan 14 09:30 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Jan 14 '26	Option Exercise	4.87	50,000	243,500	592,761	Jan 14 09:30 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Jan 14 '26	Sale	28.87	50,000	1,443,651	542,761	Jan 14 09:30 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Jan 13 '26	Sale	27.60	50,000	1,380,178	542,761	Jan 14 09:30 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Jan 12 '26	Sale	28.34	10,000	283,400	144,846	Jan 14 09:30 PM
Harmon Cyrus	Director	Jan 14 '26	Proposed Sale	29.12	3,489	101,603		Jan 14 04:20 PM
Myles David C.	Officer	Jan 14 '26	Proposed Sale	28.87	50,000	1,443,631		Jan 14 04:13 PM
Kovacs Shane William Charles	Officer	Jan 13 '26	Proposed Sale	28.01	3,822	107,069		Jan 13 04:49 PM
Myles David C.	Officer	Jan 13 '26	Proposed Sale	27.60	50,000	1,380,113		Jan 13 04:12 PM
Myles David C.	Officer	Jan 12 '26	Proposed Sale	28.34	10,000	283,363		Jan 12 12:53 PM
Harmon Cyrus	Director	Dec 22 '25	Sale	28.53	2,881	82,195	741,259	Dec 29 09:55 PM
CLARK IAN T	Director	Dec 19 '25	Option Exercise	4.61	264,800	1,219,544	264,800	Dec 23 09:42 PM
CLARK IAN T	Director	Dec 19 '25	Sale	29.73	264,800	7,873,109	0	Dec 23 09:42 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Dec 19 '25	Sale	30.46	51,000	1,553,544	551,881	Dec 23 09:41 PM
Zojwalla Naseem	Chief Medical Officer	Dec 22 '25	Option Exercise	14.07	50,000	703,392	153,997	Dec 23 09:40 PM
Zojwalla Naseem	Chief Medical Officer	Dec 19 '25	Option Exercise	15.25	40,000	610,000	173,997	Dec 23 09:40 PM
Zojwalla Naseem	Chief Medical Officer	Dec 23 '25	Option Exercise	7.02	50,000	351,000	103,997	Dec 23 09:40 PM
Zojwalla Naseem	Chief Medical Officer	Dec 22 '25	Sale	28.04	100,000	2,804,000	53,997	Dec 23 09:40 PM
Zojwalla Naseem	Chief Medical Officer	Dec 23 '25	Sale	27.66	99,509	2,752,419	4,488	Dec 23 09:40 PM
Zojwalla Naseem	Chief Medical Officer	Dec 19 '25	Sale	28.20	70,000	1,973,729	103,997	Dec 23 09:40 PM
Zojwalla Naseem	Officer	Dec 23 '25	Proposed Sale	27.66	99,509	2,752,165		Dec 23 01:31 PM
Harmon Cyrus	Officer	Dec 22 '25	Proposed Sale	28.53	2,881	82,182		Dec 22 04:09 PM
Zojwalla Naseem	Officer	Dec 22 '25	Proposed Sale	28.04	100,000	2,804,039		Dec 22 02:14 PM
Myles David C.	Officer	Dec 19 '25	Proposed Sale	30.46	51,000	1,553,447		Dec 19 04:33 PM
Zojwalla Naseem	Officer	Dec 19 '25	Proposed Sale	28.19	70,000	1,973,561		Dec 19 04:29 PM
CLARK IAN T	Director	Dec 19 '25	Proposed Sale	29.73	264,800	7,873,502		Dec 19 02:35 PM
RAPPAPORT ANDREW	Director	Nov 21 '25	Option Exercise	0.39	35,868	13,989	35,868	Nov 25 06:00 PM
Harmon Cyrus	Director	Sep 18 '25	Sale	8.33	10,000	83,300	744,140	Sep 18 09:30 PM
Harmon Cyrus	Director	Sep 16 '25	Sale	8.04	10,000	80,400	754,140	Sep 18 09:30 PM
Harmon Cyrus	Director	Sep 18 '25	Sale	8.32	3,086	25,676	117,028	Sep 18 09:30 PM
Harmon Cyrus	Director	Sep 16 '25	Sale	8.08	1,914	15,465	120,114	Sep 18 09:30 PM
Harmon Cyrus	Director	Sep 18 '25	Proposed Sale	8.33	13,086	108,978		Sep 18 02:08 PM
Harmon Cyrus	Director	Sep 16 '25	Proposed Sale	8.04	11,914	95,827		Sep 16 04:39 PM

Open in Screener

KYTX

Kyverna Therapeutics Inc

Feb 06 • 04:00PM ET

7.93

+0.66 9.08 %

Healthcare • Biotechnology • USA • NASD

KYTX Kyverna Therapeutics Inc daily Stock Chart

Peers: MRNA AMGN VRTX JNJ REGN GILD BMRN PFE BMY NVAX

| Held by: VTI VXF IBB SURI SCHA IWC AVSC DFAS SCHB DFAC

Index	-	P/E	-	EPS (ttm)	-3.72	Insider Own	38.64%	Shs Outstand	43.79M	Perf Week	-1.00%
Market Cap	453.04M	Forward P/E	-	EPS next Y	-3.47	Insider Trans	1.11%	Shs Float	35.05M	Perf Month	-8.85%
Enterprise Value	286.92M	PEG	-	EPS next Q	-0.85	Inst Own	28.80%	Short Float	9.72%	Perf Quarter	14.10%
Income	-160.99M	P/S	-	EPS this Y	-10.93%	Inst Trans	-0.81%	Short Ratio	2.29	Perf Half Y	139.58%
Sales	0.00M	P/B	2.29	EPS next Y	6.11%	ROA	-61.17%	Short Interest	3.41M	Perf YTD	-15.64%
Book/sh	3.47	P/C	2.65	EPS next 5Y	1.16%	ROE	-70.82%	52W High	13.67 -41.99%	Perf Year	142.51%
Cash/sh	3.00	P/FCF	-	EPS past 3/5Y	-75.88% -	ROIC	-105.03%	52W Low	1.78 345.51%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.96% 9.12%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-21.22%	Oper. Margin	-	ATR (14)	0.80	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.16	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	45.99	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.16	EPS Q/Q	-6.05%	SMA20	-8.04%	Beta	3.40	Target Price	29.60
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	-5.73%	Rel Volume	0.53	Prev Close	7.27
Employees	112	LT Debt/Eq	0.01	Earnings	Nov 12 AMC	SMA200	48.36%	Avg Volume	1.49M	Price	7.93
IPO	Feb 08, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	12.47% -	Trades		Volume	782,872	Change	9.08%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-20-25	Initiated	William Blair	Outperform
May-27-25	Upgrade	H.C. Wainwright	Neutral → Buy	$5
Oct-10-24	Initiated	UBS	Buy	$13
Oct-09-24	Initiated	Rodman & Renshaw	Buy	$16
Jul-03-24	Initiated	H.C. Wainwright	Neutral	$8
Mar-04-24	Initiated	Wells Fargo	Overweight	$44
Mar-04-24	Initiated	Morgan Stanley	Overweight	$40
Mar-04-24	Initiated	Leerink Partners	Outperform	$48
Mar-04-24	Initiated	JP Morgan	Overweight	$39

Feb-03-26 08:00AM	Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer (GlobeNewswire)
Jan-12-26 08:00AM	Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-05-26 08:00AM	Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference (GlobeNewswire) -7.30%
Dec-30-25 07:58AM	Kyverna Therapeutics Stock Up 41% in a Month: Here's Why (Zacks)
Dec-17-25 09:24AM	Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock (GlobeNewswire) -32.52%
10:10AM	Loading…
Dec-16-25 10:10AM	KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data (Zacks) -5.36%
09:23AM	5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026 (Zacks)
Dec-15-25 04:01PM	Kyverna Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +23.23%
06:30AM	Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome (GlobeNewswire)
03:41AM	Kyverna to seek first clearance of a CAR-T therapy for autoimmune disease (BioPharma Dive)
Dec-14-25 02:30PM	Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome (GlobeNewswire)
Dec-12-25 07:30AM	2 Strong Buy Biotech Stocks With 208% to 329% Upside Potential (Barchart) +5.02%
Nov-12-25 04:05PM	Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire) -11.60%
Nov-10-25 08:00AM	Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-03-25 08:00AM	Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance (GlobeNewswire)
06:30AM	Loading…
Oct-29-25 06:30AM	Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025 (GlobeNewswire) -5.78%
Oct-25-25 11:00AM	Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025 (GlobeNewswire)
Oct-22-25 08:00AM	Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis (GlobeNewswire) -6.58%
Oct-17-25 09:59AM	Wells Fargo Raises Kyverna Therapeutics (KYTX) PT to $27 on Confidence in KYV-101 Stiff Person Syndrome Trial Readout (Insider Monkey) -5.42%
Sep-24-25 09:05AM	Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS (GlobeNewswire)
Sep-15-25 01:02PM	Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025 (GlobeNewswire)
Aug-28-25 08:00AM	Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event (GlobeNewswire)
Aug-25-25 04:02PM	Kyverna Therapeutics to Present at Upcoming Investor Conferences in September (GlobeNewswire)
Aug-12-25 04:02PM	Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire) +14.90%
Aug-01-25 09:00AM	BioMarin Announces Appointment of Ian T. Clark to Board of Directors (PR Newswire)
Jul-29-25 10:23AM	Kyverna Appoints New CFO to Guide Next Growth Phase (Insider Monkey) -11.09%
08:30AM	Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise (PR Newswire)
Jun-30-25 09:00AM	Kyverna Therapeutics Announces Appointment of New Chief Financial Officer (PR Newswire) -6.40%
May-28-25 04:02PM	Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference (PR Newswire)
May-16-25 06:36AM	Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff (BioPharma Dive) +6.42%
04:02PM	Loading…
May-13-25 04:02PM	Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results (PR Newswire) -7.33%
Apr-17-25 07:38AM	Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode Electronics, Inc. (NYSE: MEI); ModivCare, Inc. (NASDAQ: MODV); and Monolithic Power Systems, Inc. (NASDAQ: MPWR) - Grabar Law Office Is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-27-25 04:02PM	Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire) -5.80% -15.07%
Mar-24-25 09:13AM	Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-21-25 11:29AM	Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025 (SeekingAlpha)
08:32AM	Notice to Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Rocket Lab USA, Inc. (NASDAQ: RKLB): Grabar Law Office is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-18-25 04:48PM	Notice to Long-Term Shareholders of Archer-Daniels-Midland Co. (NYSE: ADM); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Kyverna Therapeutics, Inc. (Nasdaq: KYTX); and Mercury Systems, Inc. (Nasdaq: MRCY): Grabar Law Office is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-17-25 03:01PM	Notice to Long-Term Shareholders of Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-03-25 04:05PM	Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference (PR Newswire) -8.80%
Feb-10-25 12:00PM	What Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock (Zacks)
Jan-21-25 04:05PM	Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer (PR Newswire)
Jan-17-25 05:45AM	Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX (PR Newswire)
Jan-13-25 07:30AM	Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-08-25 08:00AM	Unnatural Products Appoints Abbas Kazimi and Mert Aktar to Board of Directors (GlobeNewswire)
Jan-07-25 05:45AM	Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi and Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX (PR Newswire)
Jan-06-25 04:05PM	Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference (PR Newswire) -7.07%
Dec-27-24 05:45AM	Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi and Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX (PR Newswire)
Dec-19-24 12:16PM	Investors in Kyverna Therapeutics, Inc. Should Contact Levi and Korsinsky Before February 7, 2025 to Discuss Your Rights KYTX (GlobeNewswire)
Dec-13-24 04:05PM	Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth (PR Newswire)
Dec-09-24 06:38PM	Kyverna Therapeutics, Inc. Investors Who Have Lost Money Should Contact Block and Leviton to Find Out How They Might Recover Money Through A Recent Securities Lawsuit (GlobeNewswire) +6.81% -5.56%
Nov-14-24 10:01AM	Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024 (PR Newswire) -5.14%
Nov-13-24 04:14PM	Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results (PR Newswire)
Oct-21-24 08:00AM	Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors (PR Newswire) -7.80%
Oct-19-24 11:13AM	Kyverna Therapeutics (KYTX): Leading Nano Cap with Promising CAR T-Cell Therapy (Insider Monkey)
Oct-10-24 03:05PM	JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc (GuruFocus.com)
Sep-18-24 08:00AM	Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024 (PR Newswire)
Sep-16-24 08:00AM	Kyverna Therapeutics Announces Leadership Update (PR Newswire)
06:58AM	Kyverna swaps CEOs, leaning on Kite veterans to lead next chapter (BioPharma Dive)
Aug-21-24 04:05PM	Kyverna Therapeutics to Participate in Upcoming September Investor Conferences (PR Newswire) +13.36% -5.36%
Aug-12-24 04:08PM	Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results (PR Newswire) +7.20%
04:05PM	Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis (PR Newswire)
Jul-16-24 11:33AM	Kyverna wins RMAT designation for stiff-person syndrome for cell therapy candidate (Pharmaceutical Technology) +11.71%
08:52AM	Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product (Zacks)
Jul-15-24 04:05PM	Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome (PR Newswire)
Jun-20-24 08:55AM	Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial (PR Newswire) +7.93%
Jun-17-24 04:05PM	First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS) (PR Newswire) -17.21% -5.70%
Jun-10-24 04:05PM	Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology (PR Newswire)
Jun-07-24 08:55AM	Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024 (PR Newswire)
May-14-24 10:54PM	KYTX Stock Earnings: Kyverna Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +5.95%
04:05PM	Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results (PR Newswire)
Apr-11-24 05:01PM	Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases (PR Newswire)
Mar-29-24 02:59PM	First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med (PR Newswire)
Mar-26-24 04:05PM	Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results (PR Newswire) +6.97%
Mar-14-24 07:00AM	Why That Hot Biotech IPO Could Be a Winner (The Wall Street Journal)
Mar-07-24 07:26PM	Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis (PR Newswire)
06:14PM	How Kyverna is positioned for success on autoimmune therapy: CEO (Yahoo Finance Video)
Feb-12-24 04:39PM	Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Feb-07-24 10:29PM	Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering (PR Newswire)

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SEIDENBERG BETH C	Director	Dec 18 '25	Buy	7.50	133,333	999,998	869,317	Dec 22 11:43 AM
Westlake BioPartners Opportuni	10% Owner	Dec 18 '25	Buy	7.50	133,333	999,998	869,317	Dec 22 11:42 AM
Walker Karen Marie	Chief Technology Officer	Dec 15 '25	Option Exercise	4.83	23,998	115,910	46,634	Dec 17 08:30 PM
Walker Karen Marie	Chief Technology Officer	Dec 15 '25	Sale	12.20	23,998	292,776	22,636	Dec 17 08:30 PM
KAREN WALKER	Officer	Dec 15 '25	Proposed Sale	8.78	23,998	210,702		Dec 15 04:16 PM

SLDB

Solid Biosciences Inc

OLMA

Olema Pharmaceuticals Inc

KYTX

Kyverna Therapeutics Inc

Upgrade your FINVIZ experience